Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ClinArt Company & Signen Clinical Discoveries | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, in the following sub-populations:
In addition, the purpose is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines, overall and by country. | 6 months- One visit only, no follow up visits. |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of patients reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations - Primary/secondary prevention patients - Patients with metabolic syndrome (according to NCEP III definition). | 6 months - One visit only, no follow up visits. | |
| The proportion of patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines / national guidelines, in the following sub-populations:-Primary/secondary prevention patients -Patients with metabolic syndrome. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subject who visits the primary care clinics, cardiology clinics and internal medicine clinics, and who fulfil the inclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Prof. Mohammed Arafah | King Khalid University Hospital | Study Chair |
| Dr. Shorook Alherz | King Fahad National Guard Hospital | Principal Investigator |
| Dr. Khalid Alnemer | Security Forces Hospital | Principal Investigator |
| Dr. Hossam Alghetany | Soliman Fakieh Hospital | Principal Investigator |
| Dr. Othman Metwally | King Fahad General Hospital | Principal Investigator |
| Dr. Akram Alkhadra | King Fahad University Hospital | Principal Investigator |
| Dr. Faisal Alanizi | Ministry of Health, Saudi Arabia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Riyadh | Central | Saudi Arabia | |||
| Research Site |
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood
| 6 months- One visit only, no follow up visits. |
| Dammam |
| Eastern Province |
| Saudi Arabia |
| Research Site | Aljouf | North | Saudi Arabia |
| Research Site | Jeddah | Western | Saudi Arabia |
| Research Site | Makah | Western | Saudi Arabia |
| D009750 |
| Nutritional and Metabolic Diseases |